The US Association for Accessible Medicines has released a report doubling down on its criticisms of healthcare industry ‘middlemen’, such as health plans and pharmacy benefit managers, for blocking patient access to and delaying coverage of new generic drugs in favor of higher-priced brand drugs with high rebates.
“Patients and the health care system win when new, lower-cost generic drugs enter the market,” said David Gaugh, AAM’s interim...




